OncoMatch/Clinical Trials/NCT06547736
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Is NCT06547736 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-A2102 or/and HRS-4642 and SHR-A1904 or/and HRS-4642 for pancreatic cancer.
Treatment: SHR-A2102 or/and HRS-4642 · SHR-A1904 or/and HRS-4642 · SHR-A1811 or/and HRS-4642 · SHR-A2102, HRS4642 and Adebrelimab — The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Cannot have received: palliative radiotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify